CD8A and neoplasm: The ST‐AS&Si treatment robustly amplified anti‐tumor T cell immunity via increasing tumor‐infiltrating CD8+ T cells and decreasing immunosuppressive Treg cells, leading to remarkable suppression of tumor progression and metastasis.